GENETIC-POLYMORPHISM OF CYTOCHROMES-P450 - INTERETHNIC DIFFERENCES AND RELATIONSHIP TO INCIDENCE OF LUNG-CANCER

被引：41

作者：

INGELMANSUNDBERG, M ^{[1
]}

JOHANSSON, I ^{[1
]}

PERSSON, I ^{[1
]}

YUE, QY ^{[1
]}

DAHL, ML ^{[1
]}

BERTILSSON, L ^{[1
]}

SJOQVIST, F ^{[1
]}

机构：

[1] KAROLINSKA INST,HUDDINGE UNIV HOSP,DEPT CLIN PHARMACOL,S-14186 HUDDINGE,SWEDEN

来源：

PHARMACOGENETICS | 1992年 / 2卷 / 06期

关键词：

D O I：

10.1097/00008571-199212000-00004

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The cytochromes P450 participate in the metabolic activation of precarcinogens. Recent results reveal that many P450 genes are polymorphically distributed. Different investigators have tried to link polymorphic variants of the CYP1A1, CYP2D6 and CYP2E1 genes to the incidence of cancer, particularly lung cancer, in Asian and Caucasian populations. In the current overview we briefly summarize this research. It appears that interesting functionally linked interindividual differences in the CYP1A1 gene have been found and could be of importance in understanding differences in susceptibility to lung cancer. On the other hand, the data presented regarding CYP2D6 and CYP2E1 are less promising. We also describe interethnic differences in the P450 gene structures as a major obstacle for extrapolation of results between different ethnic groups.

引用

页码：264 / 271

页数：8

共 41 条

[1]

Ayesh R., Idle J.R., Ritchie J.C., Crothers M.J., Hetzel M.R., Metabolic oxidation phenotypes as markers of lung cancer susceptibility, Nature, 312, pp. 169-170, (1984)

[2]

Benitez J., Ladero J.M., Jara C., Carillo J.A., Cobaleda J., Llerena A., Vargas E., Munoz J.J., Polymorphic oxidation of debrisoquine in lung cancer patients, Eur J Cancer, 27, pp. 158-161, (1991)

[3]

Bertilsson L., Lou Y.Q., Du Y.L., Liu Y., Kuang T.Y., Liao X.M., Wang K.Y., Reviriego J., Iselius L., Sjoqvist F., Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin, Clin Pharmacol Ther, 51, pp. 388-397, (1992)

[4]

Broly F., Gaedigk A., Heim M., Eichelbaum M., Morike K., Meyer U.A., Debrisoquine/sparteine hydroxylation genotype and phenotype: Analysis of common mutations and alleles of CYP2D6 in a European population, DNA Cell Biol, 8, pp. 545-558, (1991)

[5]

Brosen K., Gram L.F., Clinical significance of the sparteine/debrisoquine oxidation polymorphism, Eur J Clin Pharmacol, 36, pp. 537-547, (1989)

[6]

Caporaso N.E., Tucker M.A., Hoover R.N., Hayes R.B., Pickle L.W., Issaq H.J., Muschik G.M., Green-Gallo L., Buivys D., Aisner S., Resau J.H., Trump B.F., Tollerud D., Weston A., Harris C.C., Lung cancer and the debrisoquine metabolic phenotype, J Natl Cancer Inst, 82, pp. 1264-1271, (1990)

[7]

Caporaso N., Landi M.T., Vineis P., Relevance of metabolic polymorphisms to human carcinogenesis: Evaluation of epidemiologic evidence, Pharmacogenetics, 1, pp. 4-19, (1991)

[8]

Crepsi C.L., Penman B.W., Gelboin H.V., Gonzalez F.J., A tobacco smoke-derived nitrosamine, 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic cytochrome P4502D6, Carcinogenesis, 12, pp. 1197-1201, (1991)

[9]

Dahl M.-L., Johansson I., Porsmyr Palmertz M., Ingelman-Sundberg M., Sjoqvist F., Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population, Clin Pharmacol Ther, 51, pp. 12-17, (1992)

[10]

Duche J.C., Joanne C., Barre J., De Cremoux H., Dalphin J.C., Depierre A., Brochard P., Tillement J.P., Bechtel P., Lack of relationship between the polymorphism of debrisoquine oxidation and lung cancer, Br J Clin Pharmacol, 31, pp. 533-536, (1991)

← 1 2 3 4 5 →